Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from extravascular spaces (e.g., brain, eyes) into the intravascular compartment and enhancing water excretion by the kidneys. Dextrose provides caloric supplementation, and sodium chloride provides electrolytes to maintain tonicity.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Reduction of intracranial pressure (FDA-approved for cerebral edema),Reduction of intraocular pressure in acute glaucoma,Promotion of diuresis in drug overdose (e.g., barbiturates, salicylates),Osmotic diuresis in acute renal failure prevention (e.g., during cardiovascular surgery),Adjuvant in urology for bladder irrigation (off-label),Prevention of acute kidney injury in rhabdomyolysis (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion. For osmotic diuresis: 50-100 g (1000-2000 m L of this solution) over 1-2 hours, total dose not exceeding 200 g/day. For reduction of intracranial pressure: 1.5-2 g/kg as a 20-25% solution given IV over 30-60 minutes. This 5% solution is not typically used for ICP reduction due to dilution.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Mannitol: 0.25–1.5 hours (approximately 15–90 minutes); prolonged in renal impairment. Dextrose: <30 minutes (endogenous regulation).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Mannitol is not significantly metabolized; it is freely filtered by the glomeruli and excreted unchanged in urine. Dextrose is metabolized via glycolysis and oxidative phosphorylation. Sodium chloride dissociates into ions that are handled by renal tubular transport.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >90% mannitol excreted unchanged in urine; dextrose is fully reabsorbed or metabolized; sodium chloride is handled by renal tubules.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Mannitol: 0% (not bound); dextrose: negligible; sodium: minimal.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Mannitol: ~0.3–0.7 L/kg; distributes primarily in extracellular fluid; does not cross cell membranes significantly.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% for all components.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Contraindicated in anuria due to severe renal disease or severe renal impairment (GFR <10 m L/min). Caution in mild to moderate impairment; monitor serum osmolality and electrolytes. No specific GFR-based dose adjustment established.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment for Child-Pugh class. Caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
For osmotic diuresis: 2 g/kg IV over 1-2 hours as a 15-20% solution. For cerebral edema: 1-2 g/kg IV over 30-60 minutes as a 20-25% solution. Not typically using this 5% formulation for these indications.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution due to age-related decline in renal function. Monitor renal function, fluid balance, and electrolytes. Initiate at low end of dosing range.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
May cause circulatory overload, pulmonary edema, or congestive heart failure in patients with compromised cardiac function. Monitor serum electrolytes, osmolality, and renal function. Use with caution in patients with anuria, severe renal impairment, or active intracranial bleeding (risk of expansion). Avoid extravasation (can cause tissue necrosis). Rapid administration may cause headache, nausea, or blurred vision.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Anuria (due to severe renal disease), pulmonary edema (due to fluid overload), active intracranial bleeding (unless during craniotomy), severe dehydration, established acute tubular necrosis (use may worsen), hypersensitivity to any component.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, avoid high-sodium foods to prevent exacerbation of hypernatremia.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Pregnancy Category C. Mannitol and dextrose combinations are generally considered low risk for teratogenicity. Mannitol is an osmotic diuretic that does not cross the placenta significantly at therapeutic doses. Dextrose is a normal constituent of maternal and fetal blood; however, hyperglycemia from dextrose infusion may be associated with fetal hyperinsulinism and macrosomia if maternal glucose is poorly controlled. No specific teratogenic effects have been reported for this combination. Benefit-risk assessment is required.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Mannitol and dextrose are endogenous substances or metabolites. Mannitol is excreted into breast milk in small amounts (M/P ratio unknown but likely low due to high molecular weight). Dextrose is a normal milk component. I. V. administration may raise maternal blood glucose, but effects on infant are minimal at therapeutic doses. Caution in lactation due to potential for maternal hyperglycemia.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Due to increased plasma volume (50% increase) and glomerular filtration rate (50-60% increase) in pregnancy, clearance of mannitol and dextrose may be enhanced. Monitor serum osmolarity and electrolytes; adjust infusion rate to avoid hyperosmolarity or fluid overload. No specific dose reduction required but careful titration is recommended. Blood glucose monitoring is essential to avoid maternal hyperglycemia.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor serum sodium and osmolality closely due to risk of hypernatremia and hyperosmolality; contraindicated in anuria, severe pulmonary edema, and intracranial hemorrhage. Use with caution in patients with renal impairment or congestive heart failure.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any swelling, shortness of breath, or rapid weight gain.,Do not consume additional salt in diet while receiving this infusion.,Inform healthcare provider if you have kidney problems or heart failure.,This medication may cause increased urination; keep track of fluid intake and output.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is a Electrolyte that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from extravascular spaces (e.g., brain, eyes) into the intravascular compartment and enhancing water excretion by the kidneys. Dextrose provides caloric supplementation, and sodium chloride provides electrolytes to maintain tonicity.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is: Intravenous infusion. For osmotic diuresis: 50-100 g (1000-2000 m L of this solution) over 1-2 hours, total dose not exceeding 200 g/day. For reduction of intracranial pressure: 1.5-2 g/kg as a 20-25% solution given IV over 30-60 minutes. This 5% solution is not typically used for ICP reduction due to dilution.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is classified as Category A/B. Pregnancy Category C. Mannitol and dextrose combinations are generally considered low risk for teratogenicity. Mannitol is an osmotic diuretic that does not cross the placenta sign. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.